PACB · Pacific Biosciences Of California, Inc.
$1.15
+0.00 (+0.00%)
At close · Aug 14
Market Cap
$357.46M
Shares
310.83M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.15
Open$1.15
Day$1.13–1.18
52W close$1.11–2.67
Avg vol 30d6.6M
Short int49.0M · 15.8% float · 7.4d
Short vol44%
Last earningsAug 5, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 3, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−31%
below
Price vs 50-day avg
−19%
below
RSI (14)
35
neutral
MACD trend
Negative
52-week position
3%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−20%
trailing
6-month return
−27%
trailing
YTD return
−39%
this year
Relative strength
−41%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-6% holders QoQ · +24 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
15.77% of float · ▲ +6.0% MoM · 7.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
216 holders — mid 3-yr range
Squeeze score
73
high risk · 0–100
Fundamentals
Revenue growth
+3%
Y/Y
Gross margin
49%
expanding
EPS growth
−14%
Y/Y
Free cash flow
$-113.9M
Balance sheet
$50.2M
net cash
Quant / Vol
risk profile
Volatility
85%
annualized · 1-yr
Max drawdown
−58%
past year
ATR
7.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
Annualized operating expenses
· by the end of 2027
$30M – $40M
Prior guidance
period ended
· from the Earnings Call filed Sep 30, 2025
Revenue
· full year of 2025
$155M – $160M
Guided vs delivered
· last 1 settled
Revenue
full year 2024
guided $230M – $250M
$154.01M
Miss −35.8%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−31%
Bearish
Price vs 50-day avg
−19%
Bearish
RSI (14)
35
Neutral
MACD trend
Negative
Bearish
52-week position
3%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-6% holders QoQ · +24 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
15.77% of float · ▲ +6.0% MoM · 7.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
216 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 3%
Range high $3
vs 200-day avg -31%
vs 50-day avg -19%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Annualized Revio pull-through per system | $229,000 | Q1 2026 | — |
|
|
|||
| Revio system placements | 15 | Q1 2026 | — |
|
|
|||
| Vega system placements | 27 | Q1 2026 | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PACB
this stock
Pacific Biosciences Of California, Inc.
|
$357.46M | -38.5% | +3.0% | — | 15.8% |
|
ABT
Abbott Laboratories
|
$193.78B | -11.2% | +5.7% | 31.2 | 1.3% |
|
SYK
Stryker Corp
|
$130.11B | -3.5% | +11.2% | 35.2 | 2.2% |
|
MDT
Medtronic plc
|
$116.83B | -5.0% | +8.4% | 24.5 | 1.4% |
|
BSX
Boston Scientific Corp
|
$75.11B | -45.6% | +12.5% | 21.0 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PACB | -3.0% | -20.1% | -27.2% | -17.9% | -38.5% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -3.4% | -24.6% | -41.0% | -21.8% | -52.4% |